Aphidicolin is an antibiotic of novel structure produced by the mold Cephalosporium aphidicola. It is a potent inhibitor of cellular deoxyribonucleic acid synthesis, and it also strongly inhibits the growth of herpes simplex virus both in tissue culture and in the rabbit eye. Aphidicolin is active against iododeoxyuridine-resistant herpes virus, and does not itself readily induce the formation of drug-resistant strains of herpesvirus.
In 1972, Brundret et al. (1) described the structure of an antibiotic produced by Cephalosporium aphidicola Petch. The antibiotic was named aphidicolin and has the structure shown in Fig. 1 . During the biological evaluation of aphidicolin, it was shown to have a marked inhibitory effect on the growth of deoxyribonucleic acid (DNA) viruses. This paper describes these effects in vitro and in vivo.
MATERIALS AND METHODS
Aphidicolin. C. aphidicola Petch was grown on a medium containing Czapek-Dox salts plus 5% cerelose and 0.1% yeast extract. Aphidicolin was extracted and purified by methods of Hesp et al. (manuscript in preparation). The solubility of aphidicolin in water is extremely low and in the order of a few micrograms per milliliter.
Tissue cultures. Human embryonic lung cells and primary calf kidney cells were grown in stoppered tubes (3 by 0.5 in, approximately 7.5 by 1.25 cm) medium containing 8% inactivated calf serum. When confluent, monolayers were changed to Eagle medium containing 2% calf serum or 0.2% bovine plasma albumin.
Viruses. The following strains of viruses were used: Herpes simplex types 1 and 2 (clinical isolates obtained from the Public Health Laboratory, Manchester, England), influenza A, (DSP), influenza A, (CAM), influenza A2 (Hong Kong), rhinovirus type 2, coronavirus type 229E, parainfluenza type 1, and vaccinia. Virus infectivity was titrated in tissue culture tubes of appropriate cells.
The methods for measuring the effects of aphidicolin and other drugs on the DNA and ribonucleic acid RNA synthesis of tissue culture cells by uptake of 3H-thymidine and 'H-uridine have already been described (2) .
Herpetic keratitis in rabbit eyes. Separately caged Dutch female rabbits (1-2 kg) were used throughout. One eye in each of six rabbits formed an experimental group.
The cornea was anesthetized with one drop of 4% Xylocaine and the epithelium was lightly scratched in a cross-hatch pattern by using a 27-gauge needle, care being taken not to disturb the stromal layer. A 0.1-ml virus suspension was then instilled into the lower cul-de-sac and the lids were gently rubbed together for several seconds. The corneal epithelium was examined daily after staining with fluorescein and washing with phosphate-buffered saline. Corneal lesions were graded 0 to 4, grade 0 representing no abnormality and grade 4 representing complete corneal involvement. The allocation of scores was done by one person throughout the whole of this study and was organized so that he had no knowledge of the therapy each animal was receiving.
In order to make a statistical comparison between the response of groups of animals on different treatments, the following procedure was used. The lesion scores for each group of animals were summed from the first day of treatment up to day 9 postinfection. Scores beyond 9 days were not included because after this time the lesions in the control groups usually began to heal (at least with herpes simplex type 1), and the difference between the control and the treated group became less.
The mean sum of the lesion scores was calculated for each group, and the difference between the control group mean and each drug-treatment mean was tested for statistical significance by means of Student's t test. The significance of each comparison at the 1% level of confidence is given in the figure legends. Control versus IUdR, days 0 to 9, calculated t = 15.6; difference is significant (1%) Control versus aphidicolin, days 0 to 9, calculated t = 8.40; difference is significant (1%). IUdR versus aphidicolin, days 0 to 9, calculated t = 7.20; difference not significant (1%). (0) and IUdR (0) on the growth of herpes simplex virus on the rabbit cornea. Treatment commenced 48 or 72 h after infection and continued for 6 days. Each score is the mean of four or six eyes in a single experiment. Statistics: (a) Control versus IUdR, days 2 to 9, calculated t = 8.50; difference is significant (1%). Control versus aphidicolin, days 2 to 9, calculated t = 6.60; difference is significant (1%). IUdR versus aphidicolin, days 2 to 9, calculated t = 1.917; difference not significant (1%). (b) Control versus IUdR, days 3 to 9, calculated t = 1.66; difference not significant (1%). Control versus aphidicolin, days 3 to 9, calculated t = 1.33; difference not significant (1%). IUdR versus aphidicolin, days 3 to 9, calculated t = 0.481; difference not significant (1%). 72 h before treatment was begun, the disease was well controlled by 5 days of treatment with either drug (Fig. 5) .
RESULTS
Activity of aphidicolin against IUdR-resistant herpes simplex type 1. The growth of our experimental strain of herpes simplex type 1 virus in vitro was reduced by 50% in the presence of 0.2 to 0.4 Mg of IUdR per ml. However, when virus which had been grown in the presence of 0.4 jig of the drug per ml was harvested and tested again for susceptibility to IUdR, it then required 12 ,g/ml to produce 50% inhibition. The virus was thus 30 times less sensitive to inhibition after one passage in the presence of the drug, but further passages in the drug did not increase the resistance. The development of IUdR-resistant strains of herpes virus is well known (5, 6) and may be one reason why IUdR therapy of human ocular herpesvirus is occasionally found to be ineffective (7) . Unlike IUdR, aphidicolin does not readily give rise to drug-resistant strains of virus. After six passages in the presence of 0.8 Mg of aphidicolin per ml, there was no decrease in the drug-susceptibility of the virus. Also, IUdR-resistant herpes virus is fully susceptible to aphidicolin.
As may be expected from these results, when
an IUdR-resistant strain of herpesvirus type 1 was inoculated into the rabbit eye, the severity of the keratitis could be reduced with aphidicolin, but not with IUdR (Fig. 5) aphidicolin on the growth of herpesvirus in vitro seem to be simply additive, and the effects of the two drugs together on the progress of herpetic keratitis in the rabbit cornea is only slightly greater than those either drug alone.
Aphidicolin and herpetic encephalitis. The relatively low animal toxicity of aphidicolin makes it possible to test the compound systemically in guinea pigs inoculated intracerebrally with herpes simplex virus. Pairs of guinea pigs were dosed subcutaneously or intraperitoneally with a suspension of aphidicolin at 200 mg/kg from the day of virus inoculation (100 guinea pig mean lethal dose intracerebrally) for 12 days. The drug dose was reduced to 100 mg/kg on day 6 because the animals looked unwell and were not gaining weight at the same rate as were the infected, but undosed, controls. However, there was no evidence of any protective effect of the compound in either the time of onset of symptoms or the mortality rate.
Derivatives of aphidicolin. Because of the low solubility of aphidicolin in water, the drug used at 1 and 10 mg/ml in the rabbit eye experiments was in the form of a fine suspension. Two water-soluble derivatives were made, the C17 C18 diphosphate and the C,7 monohemisuccinate sodium salt, but only the latter showed any activity in vitro, and this was only about one-quarter of the activity of aphidicolin itself ( Table 1 ). The monohemisuccinate ester sodium salt is highly soluble in water, but when it was tested in the rabbit eye, a concentration of 30 mg/ml was needed to achieve a therapeutic effect comparable to a suspension of 1 mg/ml of aphidicolin. It seems, therefore, that conferring water-soluble properties on the molecule does not increase its efficacy.
A large number of derivatives of aphidicolin have been synthesized (Hesp et al., manuscript in preparation) and tested in vitro, but those which showed activity against herpes-virus were much less active than was aphidicolin itself.
Only the C17 monoacetate was comparable in activity, and this was possibly because it may be hydrolyzed to aphidicolin in the test system. In therapeutic experiments in the rabbit eye, the curative effects of 1 mg of aphidicolin and IUdR per ml were equivalent against 40 eye ID,0 of herpesvirus. Although virtually equimolar amounts of aphidicolin and IUdR were used in these experiments (the molecular weights being 354 and 338, respectively), because aphidicolin is so poorly soluble in water, the effective concentration in true solution would be very low. Thus, on a molar basis, aphidicolin is probably considerably more potent than IUdR, and its effectiveness is limited only by its extremely low solubility in water. Unfortunately, chemical modification of aphidicolin to increase its water solubility led to a considerable loss of intrinsic anti-herpes activity.
The basis of the anti-herpes activity of aphidicolin is almost certainly an inhibition of virus DNA synthesis, although this has not been demonstrated directly. The concentration of antibiotic required to reduce herpesvirus growth by 5o0% in vitro is very close to that required to inhibit cellular DNA synthesis by 50%. Thus, the action of the antibiotic is not specific for virus DNA synthesis.
The high intrinsic potency of aphidicolin, its ability to inhibit the growth of IUdR-resistant herpesvirus, and the apparent lack of the development of drug resistance are all valuable properties of a potential anti-herpes drug. However, because its action is not specific for virus-directed DNA synthesis, aphidicolin may not offer any advantages for clinical use over other DNA antagonists.
